Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Multiple Sclerosis l: Introduction01:19

Multiple Sclerosis l: Introduction

Multiple sclerosis is a chronic autoimmune disease of the central nervous system (CNS) that affects the brain, spinal cord, and optic nerves. It is an inflammatory demyelinating disorder and a leading cause of neurological disability in young adults.EpidemiologyMS commonly begins between 20 and 40 years of age and is twice as common in women. Its exact cause remains unclear, but genetic susceptibility contributes, with higher risk in first-degree relatives and identical twins. A greater...
Drugs for Treatment of Crohn's Disease in IBD Using Glucocorticoids01:21

Drugs for Treatment of Crohn's Disease in IBD Using Glucocorticoids

Glucocorticoids, a class of anti-inflammatory drugs, are pivotal in treating moderate to severe Crohn's disease by inducing remission. They exhibit their anti-inflammatory action by inhibiting the production of inflammatory cytokines such as tumor necrosis factor (TNF)-α, interleukin (IL)-1, and chemokines like IL-8. In addition, they reduce the expression of inflammatory cell adhesion molecules and inhibit gene transcription of nitric oxide synthase, phospholipase A2, cyclooxygenase-2 (COX-2),...
Inhibitors of Viral Protein Synthesis01:30

Inhibitors of Viral Protein Synthesis

Protein synthesis is indispensable for viral replication, as viruses lack the cellular machinery required for this process and must hijack the host's translational apparatus. In response, host cells deploy a critical innate immune defense involving interferons, specialized cytokines that play a central role in inhibiting viral propagation.Upon viral detection, infected cells release interferons that bind to receptors on adjacent uninfected cells, activating the JAK-STAT signaling pathway and...

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Tobacco smoking disrupts bile acid and tryptophan metabolism in multiple sclerosis.

Multiple sclerosis (Houndmills, Basingstoke, England)·2026
Same author

Phase 2 Futility Trials in Alzheimer Disease and Mild Cognitive Impairment: A Cohort Analysis of the ADNI Data Set.

Neurology·2026
Same author

Application of the 2024 McDonald Criteria in Individuals With Nonspecific Symptoms or Incidental Imaging Findings in a Multicenter Study.

Neurology·2026
Same author

Efficacy and safety of ocrelizumab in primary progressive multiple sclerosis, including older patients and those with more advanced disease (ORATORIO-HAND): a multicentre, double-blind, randomised, placebo-controlled, phase 3b study.

Lancet (London, England)·2026
Same author

Men's health research priorities in men with multiple sclerosis.

Multiple sclerosis journal - experimental, translational and clinical·2026
Same author

Testing the Long-Term Effects of the <i>Go Sun Smart</i> Worksite Health Communication Campaign: A Group-Randomized Experimental Study.

The Journal of communication·2026
Same journal

AQP4 and MOG Characterize the Autoantibody Landscape of Checkpoint Blockade-Induced Optic Neuritis.

Annals of neurology·2026
Same journal

Five Issues of Artificial Intelligence in Science: Sailing the Ship of Theseus.

Annals of neurology·2026
Same journal

Reply to "Clinical Value of Aneurysm Wall Enhancement in Unruptured Intracranial Aneurysm".

Annals of neurology·2026
Same journal

Clinical Value of Aneurysm Wall Enhancement in Unruptured Intracranial Aneurysm.

Annals of neurology·2026
Same journal

Imaging of Neurovascular Compression in Thoracic Outlet Syndrome.

Annals of neurology·2026
Same journal

Reply to "Methodological Challenges in Interpreting SAA-Defined Imaging Subgroups in Parkinson's Disease".

Annals of neurology·2026
See all related articles

Related Experiment Video

Updated: May 14, 2026

Lumbar Intrathecal Injection of SOD1-ASOs for Precise CNS Targeting and Predictive Efficacy in Human SOD1-G93A ALS Mice
04:41

Lumbar Intrathecal Injection of SOD1-ASOs for Precise CNS Targeting and Predictive Efficacy in Human SOD1-G93A ALS Mice

Published on: February 24, 2026

Randomized study combining interferon and glatiramer acetate in multiple sclerosis.

Fred D Lublin1, Stacey S Cofield, Gary R Cutter

  • 1Corinne Goldsmith Dickinson Center for Multiple Sclerosis, Department of Neurology, and Friedman Brain Institute, Icahn School of Medicine at Mount Sinai, New York, NY 10029, USA. fred.lublin@mssm.edu

Annals of Neurology
|February 21, 2013
PubMed
Summary
This summary is machine-generated.

Combining interferon β-1a (IFN) and glatiramer acetate (GA) for relapsing-remitting multiple sclerosis showed no superior clinical benefit over single agents. However, combination therapy improved MRI metrics and GA was more effective than IFN alone in reducing relapses.

Related Experiment Videos

Last Updated: May 14, 2026

Lumbar Intrathecal Injection of SOD1-ASOs for Precise CNS Targeting and Predictive Efficacy in Human SOD1-G93A ALS Mice
04:41

Lumbar Intrathecal Injection of SOD1-ASOs for Precise CNS Targeting and Predictive Efficacy in Human SOD1-G93A ALS Mice

Published on: February 24, 2026

Area of Science:

  • Neuroimmunology
  • Clinical Neurology
  • Pharmacology

Background:

  • Relapsing-remitting multiple sclerosis (RRMS) is a chronic autoimmune disease affecting the central nervous system.
  • Interferon beta-1a (IFN) and glatiramer acetate (GA) are commonly prescribed disease-modifying therapies for RRMS.
  • Optimizing treatment strategies for RRMS remains a critical area of research.

Purpose of the Study:

  • To evaluate the efficacy of combined interferon β-1a (IFN) and glatiramer acetate (GA) compared to monotherapy in patients with relapsing-remitting multiple sclerosis.
  • To assess the impact of combination therapy on clinical relapse rates, disability progression, and magnetic resonance imaging (MRI) outcomes.
  • To compare the relative efficacy of GA versus IFN in managing RRMS.

Main Methods:

  • A double-blind, randomized, controlled trial involving 1,008 participants with RRMS.
  • Participants were randomized to receive either combination IFN+GA, IFN alone, or GA alone for 3 years.
  • Primary endpoint: reduction in annualized relapse rate. Secondary endpoints: time to confirmed disability, MSFC score, and MRI metrics.

Main Results:

  • Combination therapy (IFN+GA) was not superior to GA alone in reducing relapse risk.
  • Both combination therapy and GA were significantly more effective than IFN alone in reducing relapse risk.
  • Combination therapy demonstrated superiority over monotherapy in reducing new MRI lesion activity and total lesion volume accumulation.
  • No significant differences were observed in confirmed disability progression or MSFC scores between combination therapy and monotherapy over 36 months.
  • A post hoc analysis indicated a higher proportion of participants achieving disease activity-free status (DAFS) with combination therapy, driven by MRI findings.

Conclusions:

  • Combined IFN+GA therapy did not yield significant clinical benefits over 3 years compared to monotherapy for RRMS.
  • Glatiramer acetate (GA) proved superior to interferon β-1a (IFN) in reducing exacerbation risk.
  • Combination therapy showed improvements in specific MRI metrics, suggesting potential subclinical effects.
  • Further investigation in an extension phase will explore if observed MRI and DAFS differences predict later clinical outcomes.